John F. Crowley is a visionary advocate and leader in advancing therapies for people living with rare diseases. Currently, he is the chairman and CEO of Amicus Therapeutics, a global biotechnology company focusing on developing treatments for rare genetic diseases. John has been Amicus’ chief executive since 2005 and has overseen the company’s growth from a four-person start-up to one with operations in more than 30 countries, with 500+ employees and a market value of more than $3 billion.
His involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease, a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, John left his position at Bristol-Myers Squibb and became an entrepreneur as the co-founder, president and chief executive of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease, which he credits as ultimately saving his children’s lives. In 2001, Novazyme was acquired by Genzyme Corporation (now Sanofi), and John continued to play a lead role in the development of a drug for Pompe disease as senior vice president at Genzyme.
He has held leadership roles at several nonprofits, including the Global Genes Project as a founding board member and the Make-A-Wish Foundation as a former national chairman. John also is a member of the University Council on Science & Technology at Notre Dame and a Henry Crown Fellow at the Aspen Institute. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame.
John graduated with a B.S. in Foreign Service from Georgetown University. He additionally earned a J.D. from the University of Notre Dame Law School and an MBA from Harvard Business School. John also served as a commissioned intelligence officer in the U.S. Navy Reserve for more than a decade, assigned to the U.S. Special Operations Command and is a combat veteran of the Global War on Terrorism, with service in Afghanistan.
What is John F. Crowley's net worth?
The estimated net worth of John F. Crowley is at least $9.98 million as of February 15th, 2024. Mr. Crowley owns 697,628 shares of Intellia Therapeutics stock worth more than $9,976,080 as of November 23rd. This net worth estimate does not reflect any other assets that Mr. Crowley may own. Learn More about John F. Crowley's net worth.
How do I contact John F. Crowley?
Has John F. Crowley been buying or selling shares of Intellia Therapeutics?
John F. Crowley has not been actively trading shares of Intellia Therapeutics in the last ninety days. Most recently, John F. Crowley sold 2,500 shares of the business's stock in a transaction on Monday, October 11th. The shares were sold at an average price of $119.55, for a transaction totalling $298,875.00. Learn More on John F. Crowley's trading history.
Who are Intellia Therapeutics' active insiders?
Are insiders buying or selling shares of Intellia Therapeutics?
In the last year, insiders at the sold shares 7 times. They sold a total of 37,420 shares worth more than $1,085,489.31. The most recent insider tranaction occured on October, 2nd when CAO Michael P Dube sold 2,012 shares worth more than $38,248.12. Insiders at Intellia Therapeutics own 3.2% of the company.
Learn More about insider trades at Intellia Therapeutics. Information on this page was last updated on 10/2/2024.
